Beauty Health (SKIN)
(Real Time Quote from BATS)
$1.46 USD
+0.06 (4.29%)
Updated Aug 16, 2024 11:52 AM ET
4-Sell of 5 4
C Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SKIN 1.46 +0.06(4.29%)
Will SKIN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SKIN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SKIN
Compared to Estimates, Beauty Health (SKIN) Q2 Earnings: A Look at Key Metrics
ModivCare (MODV) Reports Q2 Loss, Misses Revenue Estimates
SKIN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
McKesson (MCK) Q4 Earnings and Revenues Lag Estimates
Other News for SKIN
Beauty Health price target lowered by $1.80 at TD Cowen, here's why
Hold Rating on Beauty Health Amidst Sales Decline and Prospects for Recovery
Beauty Health price target lowered by 75c at Canaccord, here's why
Expert Outlook: Beauty Health Through The Eyes Of 4 Analysts
The Beauty Health Company Q2 2024 Earnings: Will It Ever Be Profitable?